Alzamend Neuro (NASDAQ:ALZN) Rating Increased to Sell at Wall Street Zen
Wall Street Zen upgraded shares of Alzamend Neuro (NASDAQ:ALZN – Free Report) to a sell rating in a report published on Saturday morning. Separately, Ascendiant Capital Markets cut their price target on Alzamend Neuro from $288.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 17th. Read […]
Wall Street Zen upgraded shares of Alzamend Neuro (NASDAQ:ALZN – Free Report) to a sell rating in a report published on Saturday morning. Separately, Ascendiant Capital Markets cut their price target on Alzamend Neuro from $288.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 17th. Read […]
